Highlights

• Island Pharmaceuticals shares gained 4.00% to AUD 0.39 during the morning session on 2 July 2026 following a favourable patent announcement.

• Singapore granted a patent covering the use of ISLA-101 for flavivirus, including Dengue, and Chikungunya virus infections.

• The patent protects ISLA-101 as a standalone antiviral therapy and remains valid until 16 April 2034.

• The intellectual property expands protection beyond Dengue to include Chikungunya virus infection.

• The company believes the grant strengthens its commercial and partnering position as ISLA-101 advances through clinical development.

Shares of Island Pharmaceuticals Ltd (ASX:ILA) rose 4.00% to AUD 0.39 during the morning session on 2 July 2026, following the company's announcement that it had secured a new patent grant in Singapore for its lead antiviral program, ISLA-101. The update represents another step in expanding the company's intellectual property portfolio as it continues developing therapies targeting mosquito-borne viral diseases. The stock has delivered a notable 143.75% gain over the past year, with today's movement reflecting investor attention on the latest intellectual property milestone.

Island Pharmaceuticals is an Australian antiviral drug development company focused on diseases where treatment options remain limited. The company's development strategy centres on two clinical-stage assets, ISLA-101 and Galidesivir, targeting viral infections that present significant public health and biosecurity challenges. Through clinical development and ongoing expansion of its intellectual property portfolio, Island aims to support the long-term commercial potential of its antiviral pipeline.

Singapore Patent Expands Protection for ISLA-101

The company's latest announcement confirms that the Intellectual Property Office of Singapore has granted a patent protecting the use of ISLA-101 for the treatment of flavivirus infections, including Dengue, as well as Chikungunya virus infections.

The patent, titled "Method of Viral Inhibition" (Singapore Patent No. 10202011533P), covers the use of ISLA-101 without another antiviral agent, protecting the therapy as a standalone antiviral treatment. According to the company, this further strengthens the intellectual property supporting its lead drug candidate while broadening the scope of protection beyond Dengue alone.

The newly granted patent remains in force until 16 April 2034, providing long-term intellectual property protection for ISLA-101 within Singapore, subject to the applicable legal framework.

Protection Now Extends Beyond Dengue

While ISLA-101 has primarily been developed for Dengue, the latest patent expands its intellectual property coverage to include Chikungunya virus infection.

The company noted that Chikungunya, like Dengue, is a mosquito-borne viral disease that continues to affect populations across multiple regions globally. It also highlighted that there is no widely available antiviral treatment currently available for Chikungunya, making it another important therapeutic area within its broader development strategy.

By extending protection across both disease indications, the patent broadens the commercial scope surrounding ISLA-101 while supporting future development opportunities involving multiple mosquito-borne viral infections.

Patent Supports Long-Term Intellectual Property Strategy

Island Pharmaceuticals considers intellectual property to be a key component of its long-term development strategy.

According to the company, the Singapore patent forms part of its exclusively licensed intellectual property portfolio, which is owned by Monash University. The licence supports the ongoing clinical development and future commercialisation of ISLA-101.

The latest grant adds another layer of protection around the program and complements the company's broader strategy of building intellectual property coverage across jurisdictions that have both commercial significance and a high prevalence of mosquito-borne diseases.

Singapore Identified as an Important Asia-Pacific Market

The company highlighted Singapore's strategic importance within the Asia-Pacific region.

Dengue and other mosquito-borne viral diseases remain endemic across many countries in the region, making Singapore an important jurisdiction within Island's commercial planning.

Management noted that securing patent protection in territories where disease prevalence remains significant aligns with the company's objective of establishing commercial exclusivity across markets that could become relevant as ISLA-101 advances through development.

The patent therefore not only strengthens the company's legal protection but also supports its broader regional commercial strategy.

Commercial and Partnering Opportunities Receive Additional Support

Beyond intellectual property protection, Island Pharmaceuticals believes the latest patent enhances the commercial positioning of ISLA-101.

According to the company, the expanded patent estate may strengthen future partnering opportunities while supporting long-term commercialisation initiatives as clinical development progresses.

The company stated that it continues to actively expand and protect its intellectual property portfolio as part of its broader objective of maximising the long-term value of ISLA-101 across multiple viral disease indications.

As additional development milestones are achieved, intellectual property protection is expected to remain an important element supporting discussions with potential commercial and strategic partners.

Management Reaffirms Focus on Building the Patent Portfolio

Chief Executive Officer and Managing Director Dr David Foster said the Singapore patent further strengthens the intellectual property supporting ISLA-101 while expanding protection within a strategically important region where Dengue and other flavivirus infections continue to represent major healthcare challenges.

He also noted that maintaining and expanding the patent portfolio remains an important part of the company's broader strategy as ISLA-101 advances through clinical development.

According to management, strengthening exclusivity around the program is intended to support future partnering opportunities and long-term commercial development across Asia.

ISLA-101 Remains the Company's Lead Development Program

ISLA-101 continues to be the cornerstone of Island Pharmaceuticals' development pipeline.

The therapy has an established safety profile and is being repurposed for the prevention and treatment of Dengue fever and other vector-borne diseases. The company's development strategy seeks to address diseases where treatment options remain limited despite ongoing public health challenges.

Alongside ISLA-101, Island is also developing Galidesivir, a clinical-stage antiviral molecule that has demonstrated broad-spectrum activity across more than 20 RNA viruses. According to the company, these include viruses such as Ebola, Marburg, MERS, Zika and Yellow Fever, all of which represent areas of significant unmet medical need and potential biosecurity importance.

Together, these development programs form the basis of Island's broader antiviral strategy.

Patent Portfolio Continues to Support Clinical Development

For biotechnology companies, intellectual property protection often plays a central role alongside clinical progress.

Island Pharmaceuticals' latest announcement reflects continued efforts to strengthen legal protection surrounding ISLA-101 while clinical development continues.

The Singapore patent extends the company's protection beyond Dengue to include Chikungunya virus infection and supports standalone use of ISLA-101 as an antiviral therapy. Combined with protection extending until 16 April 2034, the latest development reinforces the company's intellectual property position in an important regional market.

What This Means for Investors

Island Pharmaceuticals' latest announcement represents an intellectual property milestone that supports the long-term development strategy for ISLA-101. The Singapore patent expands protection across additional viral indications while reinforcing commercial exclusivity in an important Asia-Pacific jurisdiction. As the company continues advancing ISLA-101 through clinical development, investors are likely to monitor further progress across both its patent portfolio and future clinical milestones, alongside any partnering or commercial developments that emerge from the program.

FAQs